Abstract
Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm caused by abnormal fusion of genes BCR and ABL1 and unregulated growth of granulocytes. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for CML. There is limited information regarding ponatinib, a third generation TKI, and endocrine dysfunction. This case describes a patient who developed new-onset primary hypothyroidism following initiation of ponatinib.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
